Oncosyne will be attending AACR 2026 in San Diego, with CEO Jarle and CTO and co-founder Peter W. Eide representing the company at the meeting.During the conference, Oncosyne will also present a scientific poster highlighting new results from our patient-derived tumoroid platform.
AACR is an important opportunity for us to engage with the global oncology research community and connect with pharma and biotech teams advancing therapies in colorectal and pancreatic cancer. We look forward to discussing how functional precision oncology approaches can support earlier translational decision making in drug development. 🔬
